Alnylam Pharmaceuticals, based in Cambridge, Massachusetts, specializes in mRNA cell therapies for autoimmune diseases, with its lead candidate Descartes-08 in Phase IIb trials for generalized myasthenia gravis. The company also develops Descartes-15 and Descartes-33, targeting B cell maturation antigen and autoimmune drivers, respectively.
Michael W Bonney sold 11,250 shares of ALNY on 18 August at $450.00 per share, worth a total of $5.1M. They now own 16,804 ALNY shares, or a 40% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
